It has to be highlighted that, while in wild-type MM only immunotherapy can be used, in BRAF-mutated MM both targeted and immunotherapies are feasible, but which is their optimal sequence (targeted prior to immunotherapy or viceversa) is not completely understood [33]. Here, BRAF is linked to Miyoshi myopathy.